As AT1R antagonism has been examined extensively against each of these AngII-induced cardiovascular diseases in experimental models, our rationale was to determine whether sacubitril would provide additive or synergistic benefits at doses of valsartan that did not have extensive effects when administered alone. Here, AGTR1 is linked to cardiovascular disorder.